title: Genomic landscape of squamous cell carcinoma of the lung.
abstract: Outcomes with standard therapy for patients with advanced squamous cell carcinoma (SQCC) of the lung have not improved significantly over the past decade using a predominantly empiric approach. Recent advances in pulmonary adenocarcinomas (ACs) have allowed the subdivision according to molecular subsets and the identification of specific molecular alterations that predict significant benefit from specific targeted therapies. Genomic alterations reported by The Cancer Genome Atlas (TCGA) Project identified a number of molecular targets that need to be studied systematically to improve the overall survival of patients with SQCC of the lung.
authors.affiliation: From the Division of Oncology, Department of Medicine, Yale University, New Haven, CT; Department of Internal Medicine, St. Luke's Hospital, Chesterfield, MO; Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO; Alvin J Siteman Cancer Center at Washington University School of Medicine, St. Louis, MO.
authors.forename: Daniel
authors.initials: D
authors.lastname: Morgensztern
authors.forename: Siddhartha
authors.initials: S
authors.lastname: Devarakonda
authors.forename: Ramaswamy
authors.initials: R
authors.lastname: Govindan
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics / Q000378:metabolism; D000077192:Adenocarcinoma of Lung; D002294:Carcinoma, Squamous Cell / Q000235:genetics* / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D015894:Genome, Human; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000378:metabolism; D058990:Molecular Targeted Therapy / Q000379:methods